Volteface: Strengthening the European Psychedelic Ecosystem: Partnership Between Octarine Bio and Clerkenwell Health

CANNANNEW REPORT

The announcement of a partnership between Clerkenwell Health and Octarine Bio signals a momentous time for the growth and development of the European psychedelic ecosystem. This exciting partnership between these innovative startups aims to advance patient access to psychedelic treatments in Europe, and improve the quality of the psychedelic medicines produced in Europe. Clerkenwell Health is a psychedelic specialist clinical research organisation, based in the UK, backed with investment from VC Fund Vine Ventures, and Angel investors. Clerkenwell Health provides clinical research support for drug developers in the UK and Europe, currently playing a vital role within the European psychedelic ecosystem. Tom McDonald, CEO of Clerkenwell Health said “It’s a real pleasure to be working with Octarine who are at the forefront of biosynthesis of a range of compounds which should enable reduced costs for patients. They have a strong pedigree in drug development which fits perfectly with the commercial and clinical expertise we have built within the Clerkenwell Health team”. Octarine Bio is a synthetic biology company based in Copenhagen, Denmark, which aims to deliver innovative cannabinoid and psychedelic treatments to improve health and wellbeing.  The company has the backing of several investors, including Oskare Capital, The Danish State Growth Fund, and Angel investors, such as Bruce Linton. Much excitement around this company comes from the innovative method they have developed for synthesising psilocybin, that is more cost effective than traditional methods; which they have so far demonstrated as a success at lab scale. Nick Milne PhD, Co-founder and CSO of Octarine said: “Our core ambition at Octarine is to advance psychedelic therapy across Europe and the world in a way that is consistent with sustainability principles while ensuring patient accessibility. We’re thrilled to be working with a company that shares our vision and is committed to making Europe a leader in…

Excerpt only …
READ MORE BELOW
Source : Volteface: Strengthening the European Psychedelic Ecosystem: Partnership Between Octarine Bio and Clerkenwell Health

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.